Io Biotech Stock Shares Owned By Insiders
IOBT Stock | USD 0.75 0.04 5.63% |
IO Biotech fundamentals help investors to digest information that contributes to IO Biotech's financial success or failures. It also enables traders to predict the movement of IOBT Stock. The fundamental analysis module provides a way to measure IO Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to IO Biotech stock.
IOBT | Shares Owned By Insiders |
IO Biotech Company Shares Owned By Insiders Analysis
IO Biotech's Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
More About Shares Owned By Insiders | All Equity Analysis
Insiders Shares | = | Executives Shares | + | Employees |
Current IO Biotech Shares Owned By Insiders | 0.23 % |
Most of IO Biotech's fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, IO Biotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
IOBT Shares Owned By Insiders Driver Correlations
Understanding the fundamental principles of building solid financial models for IO Biotech is extremely important. It helps to project a fair market value of IOBT Stock properly, considering its historical fundamentals such as Shares Owned By Insiders. Since IO Biotech's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of IO Biotech's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of IO Biotech's interrelated accounts and indicators.
Click cells to compare fundamentals
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
Competition |
Based on the latest financial disclosure, 0.235% of IO Biotech are shares owned by insiders. This is 98.45% lower than that of the Biotechnology sector and 98.34% lower than that of the Health Care industry. The shares owned by insiders for all United States stocks is 97.67% higher than that of the company.
IOBT Shares Owned By Insiders Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses IO Biotech's direct or indirect competition against its Shares Owned By Insiders to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of IO Biotech could also be used in its relative valuation, which is a method of valuing IO Biotech by comparing valuation metrics of similar companies.IO Biotech is currently under evaluation in shares owned by insiders category among its peers.
IOBT Fundamentals
Return On Equity | -0.88 | ||||
Return On Asset | -0.51 | ||||
Current Valuation | (28.76 M) | ||||
Shares Outstanding | 65.88 M | ||||
Shares Owned By Insiders | 0.23 % | ||||
Shares Owned By Institutions | 76.79 % | ||||
Number Of Shares Shorted | 200.92 K | ||||
Price To Book | 0.68 X | ||||
EBITDA | (91.23 M) | ||||
Net Income | (86.08 M) | ||||
Cash And Equivalents | 170.12 M | ||||
Cash Per Share | 5.90 X | ||||
Total Debt | 2.49 M | ||||
Debt To Equity | 0.01 % | ||||
Current Ratio | 20.94 X | ||||
Book Value Per Share | 2.02 X | ||||
Cash Flow From Operations | (71.74 M) | ||||
Short Ratio | 1.89 X | ||||
Earnings Per Share | (1.29) X | ||||
Target Price | 9.0 | ||||
Number Of Employees | 74 | ||||
Beta | 0.42 | ||||
Market Capitalization | 49.41 M | ||||
Total Asset | 150.72 M | ||||
Retained Earnings | (263.82 M) | ||||
Working Capital | 131.54 M | ||||
Net Asset | 150.72 M |
About IO Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze IO Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of IO Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of IO Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for IOBT Stock Analysis
When running IO Biotech's price analysis, check to measure IO Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IO Biotech is operating at the current time. Most of IO Biotech's value examination focuses on studying past and present price action to predict the probability of IO Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IO Biotech's price. Additionally, you may evaluate how the addition of IO Biotech to your portfolios can decrease your overall portfolio volatility.